☆ 4.5 Article

Patterns of anti-CGRP mAbs use and variation of triptan consumption following treatment initiation: A descriptive drug utilization study in the Tuscany region, Italy

HEADACHE (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Clinical Neurology

Utilization patterns, cardiovascular risk, and concomitant serotoninergic medications among triptan users between 2008 and 2018: A gender analysis in one Italian region, Tuscany

Giulia Hyeraci et al.

Summary: This study investigated the use of triptans in the Tuscany region of Italy, focusing on special user populations with inconclusive evidence on triptan safety. The results showed a higher proportion of female and older (>65 years) patients using triptans. Among these users, some had cardiovascular contraindications or possible contraindications and a certain proportion concurrently used serotonergic medications. Furthermore, women were more likely to use triptans long-term, while men were more likely to be frequent users.

HEADACHE (2023)

添加到收藏夹

Article Ophthalmology

Risk of Intraocular Pressure Increase With Intravitreal Injections of Vascular Endothelial Growth Factor Inhibitors: A Cohort Study

A. N. D. R. E. A. Spini et al.

Summary: This study aimed to evaluate the risk of intraocular pressure increase (IOPi) among nondiabetic patients using bevacizumab, aflibercept, and ranibizumab. The results showed that compared with aflibercept, bevacizumab and ranibizumab users had a higher risk of IOPi.

AMERICAN JOURNAL OF OPHTHALMOLOGY (2023)

添加到收藏夹

Article Clinical Neurology

Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: A retrospective cohort study

Luigi Francesco Iannone et al.

Summary: This study assessed the treatment response of patients who failed to respond to one monoclonal antibody to another. The results showed that switching to a second monoclonal antibody improved symptoms in some patients after three months of treatment. Therefore, switching anti-calcitonin gene related peptide monoclonal antibodies might be an effective treatment option for selected patients.

CEPHALALGIA (2023)

添加到收藏夹

Article Clinical Neurology

Maintenance of response and predictive factors of 1-year GalcanezumAb treatment in real-life migraine patients in Italy: The multicenter prospective cohort GARLIT study

Fabrizio Vernieri et al.

Summary: This study evaluated the 1-year effectiveness and tolerability of galcanezumab in real-life treatment of high-frequency episodic and chronic migraine. The results showed that a majority of patients experienced a significant reduction in monthly migraine days for at least 9 months. Triptan response, lower body mass index, and an early reduction in migraine days were identified as predictive factors for a persistent response.

EUROPEAN JOURNAL OF NEUROLOGY (2023)

添加到收藏夹

Article Clinical Neurology

Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study

Piero Barbanti et al.

Summary: This study confirms the long-term efficacy, safety, and tolerability of fremanezumab in real-life patients with high-frequency episodic migraine and chronic migraine. The drug significantly reduced the frequency of migraines and headaches during the 24-week treatment period, with minimal side effects.

JOURNAL OF HEADACHE AND PAIN (2023)

添加到收藏夹

Article Clinical Neurology

Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study

Bianca Raffaelli et al.

Summary: The cessation of CGRP(-receptor) antibodies migraine prophylaxis led to a significant increase in migraine frequency and acute medication intake over time. However, by weeks 13-16, the monthly migraine days were not significantly different from baseline values.

CEPHALALGIA (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

From Inception to ConcePTION: Genesis of a Network to Support Better Monitoring and Communication of Medication Safety During Pregnancy and Breastfeeding

Nicolas H. Thurin et al.

Summary: The ConcePTION project aims to reduce uncertainty about the safety of medication use in pregnancy and breastfeeding by building an ecosystem and leveraging a common data model. The model enables European data sources to contribute to major projects and facilitate effective deployment of distributed analytics.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)

添加到收藏夹

Article Clinical Neurology

Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score

Luigi Francesco Iannone et al.

Summary: This study evaluated the effectiveness and safety of three monoclonal antibodies against the calcitonin gene-related peptide pathway (erenumab, galcanezumab, and fremanezumab) in patients with resistant chronic migraine. The results showed that all three anti-CGRP mAbs were effective and safe, with a high percentage of patients achieving a ≥ 50% reduction in Migraine Disability Assessment (MIDAS) score.

CNS DRUGS (2022)

添加到收藏夹

Article Clinical Neurology

Real-world persistence of erenumab for preventive treatment of chronic and episodic migraine: Retrospective real-world study

Jonathan Gladstone et al.

Summary: The majority of patients prescribed erenumab remained persistent in taking the medication for at least a year after treatment initiation, with most patients initiating or escalating to a 140 mg dose.

HEADACHE (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Schwann cell endosome CGRP signals elicit periorbital mechanical allodynia in mice

Francesco De Logu et al.

Summary: This study reveals that the CGRP-mediated neuronal/Schwann cell pathway mediates allodynia associated with neurogenic inflammation, contributing to the algesic action of CGRP in mice.

NATURE COMMUNICATIONS (2022)

添加到收藏夹

Article Clinical Neurology

A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United States

Lynda J. Krasenbaum et al.

Summary: This study examined the real-world clinical characteristics and treatment patterns among patients initiating fremanezumab therapy for the prevention of migraine. The results showed high adherence and persistence to fremanezumab, with quarterly use associated with higher rates of adherence and persistence. Patients who were persistent for >= 6 months experienced significant reductions in acute and preventive migraine medication use, and some patients with comorbid depression and anxiety showed significant reductions in antidepressant and anxiolytic medication use.

JOURNAL OF HEADACHE AND PAIN (2022)

添加到收藏夹

Article Clinical Neurology

Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache

Umberto Pensato et al.

Summary: The study found that erenumab significantly reduced migraine frequency and pain medication intake in refractory chronic migraine patients with medication overuse headache. After 3 months, 51% of patients experienced a reduction of at least 50% in monthly headache days, with 20% experiencing a reduction of at least 75%. Allodynia was identified as a negative predictive factor for erenumab response, while 64% of patients clinically converted to episodic migraine without medication overuse.

NEUROLOGICAL SCIENCES (2022)

添加到收藏夹

Article Clinical Neurology

Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions

Linda Al-Hassany et al.

Summary: Migraine is the second most disabling disorder worldwide, and the pharmacology and clinical effects of CGRP-targeted drugs are not fully understood. Factors such as sex, body-mass index, age, and ethnic background may affect the pharmacokinetics of these treatments, particularly Gepants. Patient characteristics may play a more prominent role in the management of migraine as more is learned about CGRP-targeted therapies.

LANCET NEUROLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Treatment Patterns for Calcitonin Gene-Related Peptide Monoclonal Antibodies Including Galcanezumab versus Conventional Preventive Treatments for Migraine: A Retrospective US Claims Study

Oralee J. Varnado et al.

Summary: Real-world treatment patterns for CGRP mAb, specifically galcanezumab, showed higher adherence and persistence compared to standard-of-care (SOC) migraine preventive treatments.

PATIENT PREFERENCE AND ADHERENCE (2022)

添加到收藏夹

Review Clinical Neurology

European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention-2022 update

Simona Sacco et al.

Summary: This guideline evaluated the effectiveness and safety of monoclonal antibodies targeting the CGRP pathway for migraine prevention through systematic review and literature analysis, and provided updated treatment recommendations.

JOURNAL OF HEADACHE AND PAIN (2022)

添加到收藏夹

Review Clinical Neurology

The ultimate guide to the anti-CGRP monoclonal antibodies galaxy

Davide Mascarella et al.

Summary: Anti-CGRP monoclonal antibodies have shown remarkable efficacy and safety in the treatment of migraines. Real-world studies have provided additional insights beyond clinical trials, confirming the effectiveness of these revolutionary medications.

NEUROLOGICAL SCIENCES (2022)

添加到收藏夹

Correction Clinical Neurology

GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 (vol 17, pg 954, 2018)

Ali H. Mokdad

LANCET NEUROLOGY (2021)

添加到收藏夹

Article Clinical Neurology

Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study

Piero Barbanti et al.

Summary: Erenumab 70 mg is effective, safe, and well tolerated in real life. Easily obtainable clinical features might be of help in predicting patient's responsiveness.

HEADACHE (2021)

添加到收藏夹

Article Clinical Neurology

Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study

Fabrizio Vernieri et al.

Summary: The study aimed to evaluate the effect of discontinuing mAbs anti-CGRP on migraine patients. Results showed that migraine frequency and disability gradually increased after stopping the treatment, but most patients did not relapse to medication overuse or chronic migraine.

JOURNAL OF HEADACHE AND PAIN (2021)

添加到收藏夹

Article Clinical Neurology

Fremanezumab for the Preventive Treatment of Migraine: Subgroup Analysis by Number of Prior Preventive Treatments with Inadequate Response

Ladislav Pazdera et al.

Summary: The study evaluated the efficacy of monthly or quarterly fremanezumab in patients with chronic or episodic migraine who had inadequate response to 2 to 4 prior migraine preventive medications. Results showed significant improvements in efficacy with fremanezumab compared to placebo, even in patients who had previously experienced inadequate response to 4 different classes of migraine preventive medications. No significant treatment-by-subgroup interactions were observed, and adverse events were comparable between placebo and fremanezumab.

CEPHALALGIA (2021)

添加到收藏夹

Article Clinical Neurology

Impact of erenumab on acute medication usage and health care resource utilization among migraine patients: a US claims database study

Stewart J. Tepper et al.

Summary: Erenumab was associated with significantly reduced acute medication use and health care resource utilization in a real-world setting, indicating a reduction in the burden of migraine. Further research is needed to explore the use of a composite endpoint to evaluate migraine attacks.

JOURNAL OF HEADACHE AND PAIN (2021)

添加到收藏夹

Article Clinical Neurology

Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study

Piero Barbanti et al.

Summary: In a real-world setting, erenumab showed long-term effectiveness, safety, and tolerability in patients with high-frequency episodic migraine or chronic migraine with multiple prior preventive treatment failures. Positive predictors of responsiveness included allodynia in high-frequency episodic migraine, male sex, and baseline migraine frequency in chronic migraine, while negative predictors included psychiatric comorbidities and prior treatment failures in chronic migraine patients.

HEADACHE (2021)

添加到收藏夹

Article Clinical Neurology

Migraine Characteristics, Comorbidities, Healthcare Resource Utilization, and Associated Costs of Early Users of Erenumab in the USA: A Retrospective Cohort Study Using Administrative Claims Data

David Chandler et al.

Summary: This study provides descriptive information on the real-world use of erenumab in adults for migraine preventive treatment. Results show that erenumab can reduce claims for migraine characteristics and comorbidities, leading to decreased use of acute and preventive migraine medications.

PAIN AND THERAPY (2021)

添加到收藏夹

Article Clinical Neurology

Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine

David W. Dodick et al.

Summary: The study demonstrates that galcanezumab is effective in preventing episodic and chronic migraine in patients with acute medication overuse, significantly reducing the number of monthly migraine days and medication overuse rates compared to placebo.

CEPHALALGIA (2021)

添加到收藏夹

Article Clinical Neurology

Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy

Raffaele Ornello et al.

JOURNAL OF HEADACHE AND PAIN (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans

Tessa de Vries et al.

PHARMACOLOGY & THERAPEUTICS (2020)

添加到收藏夹

Review Public, Environmental & Occupational Health

The Role of European Healthcare Databases for Post-Marketing Drug Effectiveness, Safety and Value Evaluation: Where Does Italy Stand?

Gianluca Trifiro et al.

DRUG SAFETY (2019)

添加到收藏夹

Article Endocrinology & Metabolism

Patterns and trends of utilization of incretin-based medicines between 2008 and 2014 in three Italian geographic areas

Giuseppe Roberto et al.

BMC ENDOCRINE DISORDERS (2019)

添加到收藏夹

Article Clinical Neurology

Peripheral and central nervous system distribution of the CGRP neutralizing antibody [125I] galcanezumab in male rats

Kirk W. Johnson et al.

CEPHALALGIA (2019)

添加到收藏夹

Article Clinical Neurology

European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention

Simona Sacco et al.

JOURNAL OF HEADACHE AND PAIN (2019)

添加到收藏夹

Article Public, Environmental & Occupational Health

Concordance assessment of self-reported medication use in the Netherlands three-generation Lifelines Cohort Study with the pharmacy database IADB.nl: The PharmLines Initiative

Rahmat Sediq et al.

CLINICAL EPIDEMIOLOGY (2018)

添加到收藏夹

Article Clinical Neurology

Global, regional, and national burden of meningitis, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016

Joseph Raymond Zunt et al.

LANCET NEUROLOGY (2018)

添加到收藏夹

Article Clinical Neurology

Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016

Lars Jacob Stovner et al.

LANCET NEUROLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Fremanezumab for the Preventive Treatment of Chronic Migraine

Stephen D. Silberstein et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Medicine, General & Internal

A Controlled Trial of Erenumab for Episodic Migraine

Peter J. Goadsby et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Review Health Care Sciences & Services

Information bias in health research: definition, pitfalls, and adjustment methods

Alaa Althubaiti

JOURNAL OF MULTIDISCIPLINARY HEALTHCARE (2016)

添加到收藏夹

Article Pharmacology & Pharmacy

CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment

Lars Edvinsson

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)

添加到收藏夹

Review Physiology

CALCITONIN GENE-RELATED PEPTIDE: PHYSIOLOGY AND PATHOPHYSIOLOGY

F. A. Russell et al.

PHYSIOLOGICAL REVIEWS (2014)

添加到收藏夹

Review Behavioral Sciences

Seizure diaries for clinical research and practice: Limitations and future prospects

Robert S. Fisher et al.

EPILEPSY & BEHAVIOR (2012)

添加到收藏夹

Article Clinical Neurology

Italian guidelines for primary headaches: 2012 revised version

Paola Sarchielli et al.

JOURNAL OF HEADACHE AND PAIN (2012)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.